Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total Revenues	$ 30	$ 23	$ 64	$ 52
Costs and Expenses:
Production costs	69	279	147	517
Research and development	2,475	1,317	3,511	2,742
General and administrative	2,181	2,145	4,253	4,256
Total Costs and Expenses	4,725	3,741	7,911	7,515
Operating loss	(4,695)	(3,718)	(7,847)	(7,463)
(Loss) on investments	(470)		(1,404)
Interest and other income	79	51	124	120
Interest expense and other finance costs		(19)		(67)
Extinguishment of financing obligation and note payable		(2,701)		(2,701)
Gain on sale of fixed assets		216		216
Redeemable warrants valuation adjustment	3	7	34	(29)
Gain from sale of Income tax operating losses	232	288	422	469
Net Loss	(4,851)	(5,876)	(8,671)	(9,455)
Other comprehensive (loss)
Reclassification adjustment for realized investment loss		25		25
Change in unrealized loss on marketable securities available for sale		(62)		(225)
Comprehensive loss	$ (4,851)	$ (5,913)	$ (8,671)	$ (9,655)
Basic and diluted loss per share	$ (0.10)	$ (0.12)	$ (0.18)	$ (0.20)
Weighted average shares outstanding basic and diluted	48,034,100	47,832,997	48,014,713	46,805,492
Clinical Treatment Programs - US [Member]
Revenues:
Total Revenues	$ 30	$ 23	$ 64	$ 52
Clinical Treatment Programs - Europe [Member]
Revenues:
Total Revenues